Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Panel Split On Whether Cubicin Should Be Approved For Infective Endocarditis

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Anti-Infective Advisory Committee recommends use of daptomycin in S. aureus bacteremia patients.

You may also be interested in...



Cubicin Indication Expands To Cover S. Aureus Bacteremia

Cubist says daptomycin injection is the only IV antibiotic approved for S. aureus bloodstream infections.

Cubicin Indication Expands To Cover S. Aureus Bacteremia

Cubist says daptomycin injection is the only IV antibiotic approved for S. aureus bloodstream infections.

Cubist’s Feverish Weekend: Rapid Response To Friday’s Cubicin “Approvable” Letter

Firm says its March 27 response to FDA clears up labeling issues related to infective endocarditis indication for daptomycin.

Topics

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel